Toshiaki Nakano
|
Toshiaki Nakano |
||
|
Position: Associate Professor |
Lab: Division of Transplant Immunology, Liver Transplantation Center |
|
|
Education: Ph.D. |
Graduated School：Department of Molecular Biotechnology, Graduate School of Advanced Sciences of Matter, Hiroshima University, Japan |
|
|
Ext.: 407-8190 |
E-mail: nakano33@mail.cgu.edu.tw |
|
|
Personal Web Site：http://nakano-lab-cgu.strikingly.com |
||
|
Lab members: post-doc fellow 1 |
Master course 1 |
Research Assistant 1 |
|
Research interests: My major research interest is to identify molecular biomarkers for diagnosis and therapeutics in liver transplant rejection and tolerance. In our series of experimental liver transplant research using acute rejection and spontaneous tolerance models, I have demonstrated the impact of extracellular histone H1 on liver transplant rejection and the therapeutic potential of corresponding autoantibody in tolerance induction (Transplantation 2004 and 2007; Transplant Immunol 2008; J Immunol 2009; Biochem Biophys Res Commun 2013; Clin Dev Immunol 2013). Based on my present studies, my international collaborators, Hiroshima University and Josai International University, have developed immunosuppressive monoclonal antibody against histone H1 mimotope (SSV mAb). Anti-histone H1 Ab (or SSV mAb) could ameliorate not only rejection but also autoimmune hepatitis (Immunology 2010), sepsis (BioMed Res Int 2015) and type I allergy (PLoS One 2016). Besides, I have recently identified hepatic miR-301a as a rejection-specific biomarker (OMICS 2017). From the screening of the target cell-surface molecules of SSV mAb, GAPDH has been identified and its therapeutic potential for sepsis has been reported (Sci Rep 2014). The moonlight function of GAPDH for termination of immune responses through the induction of M2 macrophages has been reported (Biofactors 2018). In addition to transplant immunology research, I have organized phototherapy/vitamin D research in a past decade. Briefly, I have established non-alcoholic steatohepatitis (NASH) model in rats and demonstrated the therapeutic potential of phototherapy in NASH partly through the induction of vitamin D3 (J Hepatol 2011). This study is the first confirmation of therapeutic potency of phototherapy and Vitamin D3 supplementation in the animal model of fatty liver disease, which clearly builds the basis for subsequent human therapeutic trials in NASH. This finding is highlighted as an Editorial (Geier A. J Hepatol 2011), and leads to perform clinical trial of vitamin D3 for NASH patients in Europe by the editor’s group. In addition to the clinical impact of phototherapy in terms of the elevation of vitamin D3 in NASH patients (POL Nurs Prac Res 2018), we have demonstrated the therapeutic potential of phototherapy in experimental animal models of colitis (J Gastroenterol Hepatol 2014), allergic bronchial asthma (Adv Tech Biol Med 2014;2:1.) and food allergy (under revision). Furthermore, we have established the animal model for hepatocellular carcinoma (HCC) and demonstrated the impact of circulating exosomal miR-92b on the generation of immunosuppressive tumor microenvironment, resulting in the development and recurrence of HCC after living donor liver transplantation (LDLT). The value of exosomal miR-92b before/after LDLT may predict the risk of posttransplant HCC recurrence (Am J Transplant 2019). |
||
